As more health plans are implementing copay accumulator programs, manufacturers are struggling to find ways to counter them. In addition to the loss of patients who stop taking their drugs once they’re on the hook for larger out-of-pocket payments, drugmakers are taking another financial hit by having to increase their funding of income-based patient-assistance programs to help people hitting the annual limits on how much copay assistance they can receive due to accumulators and then shifting to patient-assistance programs. So what can companies do?
- Abstract, Medicare and Medicaid
- Datapoint, Medicare and Medicaid
- Abstract, Specialty Pharmacy
- Datapoint, Drug Benefits
- Drug Benefits